Adjuvant L-arginine treatment in controlled ovarian hyperstimulation: a double-blind, randomized study.

What Was Tested

The paper reports a study of Arginine, published as a randomized controlled trial.

To evaluate the role of L-arginine supplementation in controlled ovarian hyperstimulation, 37 IVF patients were divided into two groups according to ovarian stimulation protocols: group I, GnRH agonist plus pure (p)FSH plus oral L-arginine (n = 18); and group II, GnRH agonist plus pFSH plus placebo (n = 19).

Why It Was Studied

Enhanced vascularization appears to be important for follicular selection and maturation in both spontaneous and stimulated IVF cycles.

Nitric oxide, formed in vivo from L-arginine, may play a key role in follicular maturation and ovulation.

Who Took Part

According to the abstract, 37 patients were involved.

PubMed indexes the participants as adults, women only.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Arginine and who got the comparison, which limits bias.

Neither the patients nor the staff measuring them knew who was on Arginine, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Arginine could be set against what happens without it.

Hormonal, ultrasonographic and Doppler evaluations were performed, and plasma and follicular fluid nitrite/nitrate concentrations were monitored.

What Was Measured

The subject headings attached to it are Arginine, Chorionic Gonadotropin, beta Subunit, Human, Embryo Transfer, Embryo, Mammalian, Fertilization in Vitro, Follicle Stimulating Hormone and Follicular Fluid.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Arginine in 37 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2002 (Human reproduction (Oxford, England)), a journal based in England.

More context: all human trials.